Evidence map›Paper›PMID 34515857›Full record

ReviewCurrent treatment options in oncology2021

Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.

Manit K Gundavda, Kaival K Gundavda

Open access · bronzeAbstract readReview
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Manit K GundavdaDepartment of Surgical Oncology: Orthopedic Oncology, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, 400016, India. manit.gundavda@gmail.com.
Kaival K GundavdaDepartment of Surgical Oncology, Tata Memorial Hospital, 93, Ground Floor, Main Building, Mumbai, 400012, Maharashtra, India.
P. D. Hinduja Hospital and Medical Research Centre · INTata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementWhile emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this group's specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.

Indexed as

COVID-19COVID-19 VaccinesHumansImmune SystemImmunizationImmunocompromised HostImmunosuppression TherapyMedical OncologyNeoplasmsPatient SafetyPractice Guidelines as TopicSARS-CoV-2Treatment OutcomeVaccinationCOVID-19 VaccinesCancer careCOVID-19 vaccinationExpert recommendationsMedical oncology treatmentsPrevention of SARS-CoV-2 infectionSafety and efficacy

Identifiers

PMID34515857
PMCPMC8436191
OpenAlexW3199804648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.